Cel­gene’s Revlim­id flops in Phase III lym­phoma study, shares slide

Shares of Cel­gene were dinged Mon­day evening af­ter the Big Biotech not­ed that its top fran­chise drug Revlim­id didn’t make the cut as a main­te­nance ther­a­py for dif­fuse large B-cell lym­phoma (DL­B­CL).

While the drug hit the pri­ma­ry end­point for pro­gres­sion-free sur­vival com­pared to a place­bo in the Phase III RE­MARC study, in­ves­ti­ga­tors at the Lym­phoma Aca­d­e­m­ic Re­search Or­ga­ni­za­tion in France say it failed to make a sig­nif­i­cant dif­fer­ence in over­all sur­vival. As a re­sult, Cel­gene says it’s drop­ping plans for a reg­u­la­to­ry fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.